Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications

MP Lambert, L Rauova, M Bailey… - Blood, The Journal …, 2007 - ashpublications.org
Blood, The Journal of the American Society of Hematology, 2007ashpublications.org
Abstract Platelet factor 4 (PF4) is a negative regulator of megakaryopoiesis in vitro. We have
now examined whether PF4 regulates megakaryopoiesis in vivo by studying PF4 knockout
mice and transgenic mice that overexpress human (h) PF4. Steady-state platelet count and
thrombocrit in these animals was inversely related to platelet PF4 content. Growth of
megakaryocyte colonies was also inversely related to platelet PF4 content. Function-
blocking anti-PF4 antibody reversed this inhibition of megakaryocyte colony growth …
Abstract
Platelet factor 4 (PF4) is a negative regulator of megakaryopoiesis in vitro. We have now examined whether PF4 regulates megakaryopoiesis in vivo by studying PF4 knockout mice and transgenic mice that overexpress human (h) PF4. Steady-state platelet count and thrombocrit in these animals was inversely related to platelet PF4 content. Growth of megakaryocyte colonies was also inversely related to platelet PF4 content. Function-blocking anti-PF4 antibody reversed this inhibition of megakaryocyte colony growth, indicating the importance of local PF4 released from developing megakaryocytes. The effect of megakaryocyte damage and release of PF4 on 5-fluorouracil–induced marrow failure was then examined. Severity of thrombocytopenia and time to recovery of platelet counts were inversely related to initial PF4 content. Recovery was faster and more extensive, especially in PF4-overexpressing mice, after treatment with anti-PF4 blocking antibodies, suggesting a means to limit the duration of such a chemotherapy-induced thrombocytopenia, especially in individuals with high endogenous levels of PF4. We found that approximately 8% of 250 healthy adults have elevated (> 2 times average) platelet PF4 content. These individuals with high levels of platelet PF4 may be especially sensitive to developing thrombocytopenia after bone marrow injury and may benefit from approaches that block the effects of released PF4.
ashpublications.org